Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 367 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07464366RecruitingPhase 2
MRG003 with or without putrelimab for salivary gland cancer
This trial tests a new drug combination (MRG003 with or without putrelimab) for people with advanced salivary gland cancer that has EGFR protein. It aims to see if the treatment is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07191327Recruiting
Testing brain stimulation for posterior cortical atrophy
This study tests a noninvasive brain stimulation technique called HD-tDCS to see if it can help people with posterior cortical atrophy (PCA), a condition that affects vision and spatial skills. You would receive personalized stimulation sessions, and the study aims to learn if this treatment improves symptoms.
Ann Arbor, MichiganAges 50 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06477991Recruiting
No surgery after immunotherapy for MSI-H colorectal cancer
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Kunming, YunnanAges 18–75 - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT07016152RecruitingPhase 1
A study of a Klebsiella vaccine for healthy adults
This trial tests a new two-part vaccine (CHO-V08) to prevent Klebsiella pneumoniae infection. It looks at safety and immune response in healthy adults aged 18 to 50.
TaipeiAges 18–50 - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT07610941RecruitingPhase 1
Testing a new cancer drug alone and combined with others
This early-stage trial tests a new experimental drug (MST-0312) in people with solid tumors like lung cancer, melanoma, bladder cancer, colorectal cancer, or triple-negative breast cancer. The goal is to find safe doses and see how well it works, either by itself or paired with other treatments.
BarcelonaAges 18 years+ - NCT07351903RecruitingPhase 1
GK01 with or without chemo after surgery for solid tumors
This trial tests an investigational drug called GK01, given alone or with chemotherapy, after surgery to remove a solid tumor. The goal is to see if it helps prevent the cancer from coming back.
TianjinAges 18–70 - NCT07201376Recruiting
Testing a skin imaging device for non-melanoma skin cancer
This study tests a device that uses a special light to image skin lesions after applying an FDA-approved cream. It aims to see if the device can help doctors see benign skin growths more clearly before they are removed.
Lebanon, New HampshireAges 18 years+ - NCT07125066Enrolling by invitationPhase 1
Testing ACER-001 for combined D,L-2 hydroxyglutaric aciduria
This trial tests a drug called ACER-001 in a single patient with a rare metabolic disorder. The goal is to see if the drug helps manage symptoms.
Pittsburgh, PennsylvaniaAges Any age - NCT06714864RecruitingPhase 4
Preventing catheter infections in children on dialysis
This study tests a liquid that is put into the dialysis catheter after each session to prevent infections that can happen through the catheter. It is designed for children up to age 18 who need hemodialysis through a catheter.
Birmingham, AlabamaAges Up to 17 years - NCT07747324RecruitingPhase 1/Phase 2
Testing ayahuasca for psychogenic non-epileptic seizures
This trial tests whether a single dose of ayahuasca, a plant-based brew, can reduce psychogenic non-epileptic seizures (PNES). It may help if you are willing to stop psychiatric medications temporarily and have no other serious mental health conditions.
Ribeirão Preto, São PauloAges 18–60 - NCT07504458RecruitingPhase 3
Study of QTX-2101 for adults with a type of leukemia
This trial tests a new drug, QTX-2101, in people with acute promyelocytic leukemia (APL) that is low- or intermediate-risk. The study aims to see if the drug works and is safe for those who qualify.
Birmingham, AlabamaAges 18–71 - NCT07747103RecruitingPhase 3
Porcine thyroid extract for hypothyroidism
This trial tests a new porcine (pig) thyroid hormone replacement tablet for people with primary hypothyroidism (underactive thyroid). It aims to see if this treatment is safe and effective compared to current levothyroxine therapy.
Modesto, CaliforniaAges 18–75 - NCT06617793RecruitingPhase 1/Phase 2
Testing YTB323 for active relapsing multiple sclerosis
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
Darlinghurst, New South WalesAges 18–60 - NCT06922110Enrolling by invitationPhase 3
Long-term study of azetukalner for depression
This study is for people who already completed a previous trial of azetukalner for major depressive disorder. It tests the long-term safety and effects of continuing the medication.
Phoenix, ArizonaAges 18 years+ - NCT07300241RecruitingPhase 1
Study of NEO-811 for advanced kidney cancer
This trial tests a new drug called NEO-811 for people with advanced clear cell kidney cancer that has spread and can't be removed with surgery. The goal is to see if it helps when other treatments have stopped working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT07187973RecruitingPhase 1
Study of DISC-3405 for people with sickle cell disease
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
Birmingham, AlabamaAges 18 years+ - NCT07517263RecruitingPhase 3
Long-term Safety Study of Pelacarsen Treatment
This study follows patients who completed an earlier pelacarsen trial to check if the treatment remains safe and well-tolerated over time. Pelacarsen is an experimental medicine being tested for heart and cholesterol health.
Andalusia, AlabamaAges 18–100 - NCT07543120RecruitingPhase 2
Extended Safety Study of QCZ484 Blood Pressure Medication
This is a continuation study for people who completed a previous QCZ484 trial and tolerated it well. Researchers will monitor how safe and effective the medication remains with longer-term use for managing high blood pressure.
Garden Grove, CaliforniaAges 18 years+ - NCT06169397Enrolling by invitationPhase 2
Extension study of XTMAB-16 for pulmonary sarcoidosis
This study is an extension of a previous trial for the drug XTMAB-16 in people with pulmonary sarcoidosis. It allows patients who completed the earlier study to continue receiving the treatment and be monitored for safety and effectiveness.
Denver, ColoradoAges 18–80 - NCT06274801RecruitingPhase 3
Long-term study of seralutinib for pulmonary arterial hypertension
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
Fresno, CaliforniaAges 18–75
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 367 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.